AstraZeneca：TRUQAP®Capivasertib was approved for marketing in the United States.
Biokin：BL-B01D1 has initiated its 13th Phase III clinical trial.
Trinomab：The IPO registration has become effective.
CSPC：SYH2095 has received its first clinical trial approval.
CSPC：SYS6051 has received its first clinical trial approval.
CSPC：SYH2059 has received its first clinical trial approval.
CSPC：SYS6055 has received its first clinical trial approval.
Biokin：BL-B01D1 has been formally accepted for review.
BrightGene：BGM0504 has been formally accepted for review.
Alphamab Oncology:Anbenitamab is planned to be submitted for marketing approval.
